YuanShi Technology Raises Nearly RMB 100M for Virtual-Cell AI
YuanShi Technology has completed angel and angel-plus funding rounds totaling nearly RMB 100 million, according to MIT Technology Review Chinese. The company said the proceeds will fund model development, data and experimental-platform construction, and validation for drug-development use cases. Former Arc Institute researcher Dong Mingze has joined full-time as CTO. The company is pursuing generalizable cell models that transfer biological knowledge to new cell types and perturbation conditions, using large-scale transcriptomic data with new model architectures. It also plans to build an automated experimental and data-production platform in which model predictions can guide experiments.
The financing provides funding for model, experimental-platform and drug-development validation work, while Dong Mingze's full-time CTO role is intended to advance the company's model and data-platform programs.
过去几年,AI 已经能够预测蛋白质结构、设计药物分子,但对于一个更基础的问题,研究人员仍然难以给出准确答案:当某种药物进入细胞后,究竟会发生什么?
这也是当前 AI 制药面临的一项重要局限。模型可以帮助研究人员更快地筛选候选分子,却很难准确预测这些分子在真实生物系统中的作用。于是,一些研究者开始将目光从单个分子转向完整的细胞,希望利用 AI 建立能够预测细胞状态及其变化的虚拟细胞。
这个方向,也让两位在北京大学相识的研究者产生了交集。
吴佳奇本科是生物信息学方向,后来在北京大学攻读系统生物学博士。系统生物学的研究思路是利用数学方程描述基因调控网络、预测细胞的动态变化,但她逐渐发现,真实生物系统的复杂程度远远超出了传统模型的描述能力。